 50 PM / Updated 8 minutes ago BRIEF-Cellect Announces Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation Reuters Staff 1 Min Read 
Jan 16 (Reuters) - Cellect Biotechnology Ltd: 
* CELLECT ANNOUNCES OPENING OF A SECOND CLINICAL TRIAL SITE AND APPROVAL FROM SAFETY BOARD (DSMB) FOR DOSE ESCALATION 
* CELLECT BIOTECHNOLOGY - ‍SIGNED AGREEMENT WITH HADASSAH MEDICAL CENTER TO CONDUCT CLINICAL TRIALS ON CANCER PATIENTS IN CO‘S ONGOING PHASE I/II STUDY​ 
* CELLECT BIOTECHNOLOGY -‍ GOT APPROVAL FROM DSMB TO ESCALATE APOGRAFT FASL PROTEIN DOSAGE TO 25 NG/ML, ENROLL 3 ADDITIONAL PATIENTS FOR CLINICAL TRIAL​ Source text for Eikon: Further company coverage: